Northwestern University Human Resources

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1851-01-28

Employees: 5K

Market Cap: -

Website: https://www.venturecat.northwestern.edu

Clinical Trials

Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Liver Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-11

Lead Sponsor: Northwestern University

Target Recruit Count: 8

Registration Number: NCT00057980

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer
Lung Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-11

Lead Sponsor: Northwestern University

Registration Number: NCT00058006

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States

and more 1 locations

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-11

Lead Sponsor: Northwestern University

Registration Number: NCT00057993

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: Carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-01

Lead Sponsor: Northwestern University

Target Recruit Count: 44

Registration Number: NCT00058292

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Dietary Supplement: genistein
Procedure: conventional surgery

First Posted Date: 2003-04-09

Last Posted Date: 2012-07-19

Lead Sponsor: Northwestern University

Target Recruit Count: 36

Registration Number: NCT00058266

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
🇺🇸
Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States

and more 2 locations

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

Phase 3

Terminated

Conditions: Osteoporosis
Prostate Cancer

Interventions: Dietary Supplement: cholecalciferol
Drug: calcium gluconate
Drug: zoledronic acid

First Posted Date: 2003-04-09

Last Posted Date: 2020-12-08

Lead Sponsor: Northwestern University

Target Recruit Count: 53

Registration Number: NCT00058188

Locations: 🇺🇸
John H. Stroger Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States

Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: alemtuzumab

First Posted Date: 2003-04-09

Last Posted Date: 2019-02-06

Lead Sponsor: Northwestern University

Target Recruit Count: 37

Registration Number: NCT00057967

Locations: 🇺🇸
Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
🇺🇸
Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-06

Lead Sponsor: Northwestern University

Registration Number: NCT00004231

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004899

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004907

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy